Fiocruz Waiting for Oxford’s Covid-19 Vaccine Approval to Begin Production

Machinery and supplies are being prepared in advance due to the pandemic emergency. Preliminary results point to the vaccine's efficacy, which is in its final trial stage.

RIO DE JANEIRO, BRAZIL - The Bio-Manguinhos vaccine manufacturing facility at the Oswaldo Cruz Foundation, in northern Rio, is considered the largest in Latin America and is preparing to produce the Covid-19 vaccine developed by Oxford University in the United Kingdom.

The Oxford vaccine is in stage 3, the final stage, which will determine its efficacy on a large number of subjects. The British university this week announced that preliminary trials suggest the vaccine is safe and has induced an immune response in volunteers.

The agreement between Fiocruz and AstraZeneca, the pharmaceutical company that acquired the vaccine from Oxford . . .

To read the full NEWS and much more, Subscribe to our Premium Membership Plan. Already Subscribed?